File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence

TitleTransarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence
Authors
KeywordsHepatocellular carcinoma
Inoperable
Recurrence
Transarterial chemoembolization
Issue Date2000
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/31873
Citation
Journal Of Surgical Oncology, 2000, v. 73 n. 2, p. 109-114 How to Cite?
AbstractBackground and Objectives: The role of transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC) has remained controversial, and its efficacy for postresection intrahepatic recurrence has not been fully assessed. A study was performed to evaluate the treatment results and prognostic factors of TACE treatment in these patients. Methods: Clinicopathologic data and treatment results of 384 patients with inoperable HCC and 100 patients with postresection recurrent HCC treated with TACE were collected prospectively and analyzed. Results: TACE was associated with an overall treatment morbidity rate of 23% (112/484) and mortality rate of 4.3% (21/484). A particularly high mortality rate of 20% (9/45) was observed among patients with tumors > 10 cm and pretreatment serum albumin level ≤ 35 g/L. The overall 1-year, 3-year, and 5-year survival rates from the time of first TACE treatment were 49%, 23%, and 17% respectively. Tumor size ≤ 10 cm and serum albumin level > 35 g/L were independent favorable prognostic factors. TACE in patients with postresection recurrent HCC was associated with less morbidity, mortality, and a better survival outcome compared with patients with primary inoperable HCC, but this was largely related to smaller tumor size and better liver function in the former group at the time of TACE treatment. Conclusions: TACE in patients with inoperable HCC was associated with significant morbidity and mortality, and the survival benefit was limited. Better patient selection in terms of tumor size and liver function may improve treatment results. Patients who have a tumor > 10 cm and poor liver function (serum albumin ≤ 35 g/L) may not be suitable candidates for TACE treatment. (C) 2000 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/83971
ISSN
2015 Impact Factor: 3.151
2015 SCImago Journal Rankings: 1.349
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorNgan, Hen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorLiu, CLen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2010-09-06T08:47:23Z-
dc.date.available2010-09-06T08:47:23Z-
dc.date.issued2000en_HK
dc.identifier.citationJournal Of Surgical Oncology, 2000, v. 73 n. 2, p. 109-114en_HK
dc.identifier.issn0022-4790en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83971-
dc.description.abstractBackground and Objectives: The role of transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC) has remained controversial, and its efficacy for postresection intrahepatic recurrence has not been fully assessed. A study was performed to evaluate the treatment results and prognostic factors of TACE treatment in these patients. Methods: Clinicopathologic data and treatment results of 384 patients with inoperable HCC and 100 patients with postresection recurrent HCC treated with TACE were collected prospectively and analyzed. Results: TACE was associated with an overall treatment morbidity rate of 23% (112/484) and mortality rate of 4.3% (21/484). A particularly high mortality rate of 20% (9/45) was observed among patients with tumors > 10 cm and pretreatment serum albumin level ≤ 35 g/L. The overall 1-year, 3-year, and 5-year survival rates from the time of first TACE treatment were 49%, 23%, and 17% respectively. Tumor size ≤ 10 cm and serum albumin level > 35 g/L were independent favorable prognostic factors. TACE in patients with postresection recurrent HCC was associated with less morbidity, mortality, and a better survival outcome compared with patients with primary inoperable HCC, but this was largely related to smaller tumor size and better liver function in the former group at the time of TACE treatment. Conclusions: TACE in patients with inoperable HCC was associated with significant morbidity and mortality, and the survival benefit was limited. Better patient selection in terms of tumor size and liver function may improve treatment results. Patients who have a tumor > 10 cm and poor liver function (serum albumin ≤ 35 g/L) may not be suitable candidates for TACE treatment. (C) 2000 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/31873en_HK
dc.relation.ispartofJournal of Surgical Oncologyen_HK
dc.rightsJournal of Surgical Oncology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectInoperableen_HK
dc.subjectRecurrenceen_HK
dc.subjectTransarterial chemoembolizationen_HK
dc.titleTransarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrenceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-4790&volume=73&spage=109&epage=114&date=2000&atitle=Transarterial+chemoembolization+for+inoperable+hepatocellular+carcinoma+and+postresection+intrahepatic+recurrenceen_HK
dc.identifier.emailPoon, RTP: poontp@hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>3.0.CO;2-Jen_HK
dc.identifier.pmid10694648-
dc.identifier.scopuseid_2-s2.0-0033995209en_HK
dc.identifier.hkuros48249en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033995209&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume73en_HK
dc.identifier.issue2en_HK
dc.identifier.spage109en_HK
dc.identifier.epage114en_HK
dc.identifier.isiWOS:000085658000011-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridNgan, H=7102173824en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridLiu, CL=7409789712en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats